Navigation Links
Cardiome To Release 2008 First Quarter Results
Date:5/12/2008

bel safety study evaluating recent-onset AF patients, called ACT 4, has completed.

Vernakalant (oral) is being investigated as a chronic-use oral drug for the maintenance of normal heart rhythm following termination of AF. Cardiome announced positive results from a Phase 2a pilot study for vernakalant (oral) in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.

In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.

Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQ National Market (CRME).

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospect
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardiome To Release 2007 Results
2. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
3. Cardiome And Astellas Announce Regulatory Update
4. Cardiome to Hold Investor Update Call
5. Cardiome Updates Guidance
6. Cardiome Initiates Phase 1 Study for GED-aPC
7. Cardiome To Release Third Quarter Results
8. Cardiome to Present at CIBC Conference
9. Cardiome to Present at ThinkEquity Conference
10. Cardiome to Present at Bear Stearns Conference
11. Dynatronics to Release Third Quarter Results Wednesday, May 14, 2008; Conference Call Set for 2:30 p.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Federally Qualified Health Centers (FQHCs) granted new patient ... higher rates than other primary care practices (non-FQHCs), ... to results of a new 10-state University of ... Care . , Using data from a previous ... the investigators found that FQHCs community health ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Glycodrive ... Star Nutraceuticals designed to help maximize lean, strong muscle ... the body’s absorption of glucose has caught the attention ... “The main purpose behind Glycodrive is to help the ... muscle,” reports Michaels. “Carbs are essential in the muscle-building ...
(Date:9/30/2014)... N.C. (PRWEB) September 30, 2014 The ... an option to help diabetics curb their sweet tooth, ... Nature this September, suggests that zero-calorie sweeteners ... type 2 diabetes. , The Weizmann Institute of ... they fed artificial sweeteners to mice, the mice developed ...
(Date:9/30/2014)... 2014 With the flu season ... every day, it’s a perfect time to announce ... system is an electro-static disinfectant delivery system that ... normally missed with spray-on disinfectant applicators. , The ... an electrostatic negative charge to the disinfecting solution. ...
(Date:9/30/2014)... September 30, 2014 Two revolutionary procedures now ... treatment of gum disease a far less painful and ... , “If you’ve ever felt electric shock waves surge through ... a cold beverage, it’s possible you already know the impact ... is a general dentist in West Palm Beach, and a ...
Breaking Medicine News(10 mins):Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Columbus Janitorial Company Announces New Disinfecting System for your workplace 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3
... and Bioengineering (NIBIB) Laboratory of Bioengineering and Physical Science ... visualize fine details of cell structure three-dimensionally in thick ... organized and how they function. The work is described ... Nature Methods . The new electron tomography ...
... , , ... GTIV ), a leading provider of comprehensive home health ... the Company,s Board of Directors: Philip R. Lochner, Jr., Sheldon ... appointments, Gentiva has re-established an independent majority on its Board ...
... - NUCRYST Pharmaceuticals, a developer and manufacturer of ... Wound Management division of Smith Nephew ... Flex3 and Acticoat(TM) Flex7. The Flex range is ... dressings with NUCRYST,s proprietary SILCRYST(TM) nanocrystalline silver coatings. ...
... , , NEW YORK, Sept. ... is hosting a kick off cocktail reception to announce its Second ... the National Football League. The main event, The Journey of ... Rock Cafe with actress Lorraine Bracco and comedian Penny Marshall serving ...
... CAMBRIDGE, Mass., Sept. 3 Satori Pharmaceuticals Incorporated ... disease, Parkinson,s disease, and other neurodegenerative disorders, today announced that ... its Board of Directors. , , "We ... to our board," said Dr. Jeffrey Ives, Satori CEO. ...
... , , MIAMI BEACH, ... Oprah have spent years yo-yo dieting, but would they work so ... the extra pounds? These days, Fat is Fabulous, with reality shows ... zaftig women competing in dance-offs, bringing in big ratings numbers for ...
Cached Medicine News:Health News:NIBIB scientists increase imaging efficiency in cell structure studies 2Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 2Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 3Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 4Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 5Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 6Health News:European Launch of Acticoat(TM) Flex with NUCRYST's Nanocrystalline Silver Technology Announced by Smith Nephew 2Health News:European Launch of Acticoat(TM) Flex with NUCRYST's Nanocrystalline Silver Technology Announced by Smith Nephew 3Health News:European Launch of Acticoat(TM) Flex with NUCRYST's Nanocrystalline Silver Technology Announced by Smith Nephew 4Health News:Brain Injury Association of New York State to Host Kick Off Cocktail Reception 2Health News:Steven Holtzman Joins Satori Pharmaceuticals' Board of Directors 2Health News:Steven Holtzman Joins Satori Pharmaceuticals' Board of Directors 3Health News:Steven Holtzman Joins Satori Pharmaceuticals' Board of Directors 4Health News:85% of Single Men Would Date Heavy Women; 90% of Single Women Feel Men Can't See Past a Few Extra Pounds, States Date.com 2Health News:85% of Single Men Would Date Heavy Women; 90% of Single Women Feel Men Can't See Past a Few Extra Pounds, States Date.com 3Health News:85% of Single Men Would Date Heavy Women; 90% of Single Women Feel Men Can't See Past a Few Extra Pounds, States Date.com 4
(Date:9/30/2014)... September 30, 2014 ... the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, ... and Reagents], Application (Immunology, Oncology) & by ... published by MarketsandMarkets, provides a detailed overview ... current market trends, and strategies impacting the ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 The ... Growing ageing population and rise in the incidence of ... chronic wounds and in affordability of better quality of ... wound care market. Universal coverage of public health insurance ... would further stimulate demand. Based on the findings of ...
(Date:9/30/2014)... 2014 BioStructures, LLC has been awarded ... Tissue Banks (AATB), it was announced today by ... Accreditation follows an intensive nine-month process, including ... inspector.  It establishes that the level of medical, ... or exceeds the standards set by the AATB.  ...
Breaking Medicine Technology:Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4China Wound Care Market 2China Wound Care Market 3Biostructures, LLC Earns AATB Accreditation 2
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
Inquire...
Medicine Products: